4.55%
-2.54%
-14.18%
-38.50%
-85.41%
-77.36%
-84.67%
AI Spotlight on ATNM
Create a Free account
Company Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies.Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.
It has collaboration with Astellas Pharma, Inc.to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors.The company was incorporated in 2000 and is based in New York, New York.
Market Data
| Last Price | 1.15 |
| Change Percentage | 4.55% |
| Open | 1.11 |
| Previous Close | 1.1 |
| Market Cap ( Millions) | 36 |
| Volume | 113980 |
| Year High | 10.24 |
| Year Low | 1.07 |
| M A 50 | 1.23 |
| M A 200 | 3.36 |
Financial Ratios
| FCF Yield | -97.06% |
| Dividend Yield | 0.00% |
| ROE | -100.85% |
| Debt / Equity | 4.48% |
| Net Debt / EBIDTA | 174.28% |
| Price To Book | 0.94 |
| Price Earnings Ratio | -0.87 |
| Price To FCF | -1.03 |
| Price To sales | 442.9 |
| EV / EBITDA | 0.93 |
News
- Dec -11 - My Top 2 Stock Picks For A 2025 Rebound
- Nov -19 - SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
- Nov -18 - Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
- Nov -04 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm
- Nov -03 - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
- Nov -02 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -27 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -26 - The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
- Oct -23 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -20 - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Possible Securities Fraud
- Oct -19 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -18 - All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
- Oct -18 - The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
- Oct -18 - Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production
- Oct -17 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -15 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -14 - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc's Possible Securities Fraud
- Oct -13 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Oct -12 - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Possible Securities Fraud
- Oct -11 - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Radiotherapies
Expected Growth : 15.4 %
What the company do ?
Actinium Pharmaceuticals' Radiotherapies are targeted alpha-therapy treatments that utilize Actinium-225, a radioactive isotope, to selectively kill cancer cells while minimizing harm to healthy cells.
Why we expect these perspectives ?
Growing demand for targeted cancer therapies, increasing adoption of alpha-therapy, and Actinium-225's potential to selectively kill cancer cells while minimizing harm to healthy cells drive the market growth.
Actinium Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| Iomab-B | A CD45-targeting radioimmunotherapy for the treatment of relapsed or refractory acute myeloid leukemia (AML) |
| Actimab-A | A CD33-targeting radioimmunotherapy for the treatment of newly diagnosed AML |
| Actimab-M | A melanoma-targeting radioimmunotherapy for the treatment of metastatic melanoma |
Actinium Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Actinium Pharmaceuticals, Inc. is medium due to the presence of alternative cancer treatments, but the company's focus on targeted alpha therapy provides a unique value proposition.
Bargaining Power Of Customers
The bargaining power of customers is low for Actinium Pharmaceuticals, Inc. as the company's products are primarily used in hospitals and clinics, and patients have limited negotiating power.
Bargaining Power Of Suppliers
The bargaining power of suppliers is medium for Actinium Pharmaceuticals, Inc. as the company relies on a few key suppliers for raw materials, but has some flexibility to negotiate prices.
Threat Of New Entrants
The threat of new entrants is high for Actinium Pharmaceuticals, Inc. due to the growing interest in targeted alpha therapy and the potential for new companies to enter the market.
Intensity Of Rivalry
The intensity of rivalry is high for Actinium Pharmaceuticals, Inc. due to the competitive landscape of the pharmaceutical industry and the presence of established players.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 5.49% |
| Debt Cost | 3.95% |
| Equity Weight | 94.51% |
| Equity Cost | 4.38% |
| WACC | 4.36% |
| Leverage | 5.81% |
Actinium Pharmaceuticals, Inc. : Quality Control
Actinium Pharmaceuticals, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OABI | OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies … |
| SYRS | Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates … |
| XERS | Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for … |
| MNKD | MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
MannKind
A-Score
1-Year Total Return ->
🥈
Xeris Biopharma
A-Score
1-Year Total Return ->
🥉
OmniAb
A-Score
1-Year Total Return ->
4
Kymera Therapeutics
A-Score
1-Year Total Return ->
5
Syros Pharmaceuticals
A-Score
1-Year Total Return ->
6
